Cagrilintide/CAS:1415456-99-3

Product Features：Scientific research purposes, metabolism and obesity research direction.

Cagrilintide is a long-acting GLP-1/AMYR dual receptor agonist developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. As a high-purity peptide API, our product meets pharmaceutical grade standards, is GMP certified, and comes with COA (Certificate of Analysis) and MSDS (Material Safety Data Sheet) for full traceability. We support custom synthesis and bulk orders to meet R&D, clinical, and commercial production needs.